Rocapuldencel-T

Drug Profile

Rocapuldencel-T

Alternative Names: AGS-003; AGS-003-LNG

Latest Information Update: 20 Dec 2016

Price : $50

At a glance

  • Originator Argos Therapeutics Inc
  • Developer Argos Therapeutics Inc; GU Research Network; National Cancer Institute (USA); Roswell Park Cancer Institute
  • Class Cancer vaccines; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Renal cell carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Renal cell carcinoma
  • Phase II Non-small cell lung cancer

Most Recent Events

  • 14 Dec 2016 Argos Therapeutics Enters into strategic research agreement with Personalis for use of ACE ImmunoID™ next-generation sequencing (NGS) platform
  • 07 Dec 2016 Argos Therapeutics announces intention to submit BLA to the US FDA for rocapuldencel-T
  • 28 Oct 2016 National Cancer Institute plans a phase II trial for Bladder cancer (Metastatic disease, Combination therapy, Neoadjuvant therapy) in USA (NCT02944357)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top